Minerva Neurosciences (NERV) Set to Announce Quarterly Earnings on Wednesday

Key Points

• Minerva Neurosciences is expected to report Q3 2026 results before the market opens on November 4. Analysts forecast a loss of $0.14 per share; the earnings call is scheduled for November 5 at 12:30 p.m. ET.
• The company previously reported a Q2 loss of $0.14 per share, beating the consensus estimate of a $0.19 loss. Analysts project full-year and next-year losses of $0.73 and $0.42 per share, respectively.
• NERV shares have weakened significantly, opening at $2.23 versus a 52-week high of $8.80. Analyst sentiment is mixed, with an average “Hold” rating and a consensus price target of $10.33.

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.14) per share for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:30 PM ET.

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. On average, analysts expect Minerva Neurosciences to post ($0.73) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.

Minerva Neurosciences Stock Performance

NASDAQ NERV opened at $2.23 on Wednesday. The stock has a fifty day moving average of $3.64 and a 200-day moving average of $4.91. The stock has a market capitalization of $106.29 million, a P/E ratio of -0.08 and a beta of -0.10. Minerva Neurosciences has a 52 week low of $2.12 and a 52 week high of $8.80.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NERV. Wall Street Zen raised shares of Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Minerva Neurosciences from a "strong sell" rating to a "hold" rating in a report on Friday, October 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Minerva Neurosciences in a research note on Monday, September 21st. Finally, Jefferies Financial Group raised shares of Minerva Neurosciences from a "hold" rating to a "mixed" rating and lifted their target price for the stock from $7.50 to $10.00 in a report on Friday, August 14th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Minerva Neurosciences presently has an average rating of "Hold" and a consensus target price of $10.33.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company's research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.

Minerva's lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.